IASLC News

When the initial molecular report suggested a ROS1 rearrangement, crizotinib was started in expectation of a typically great response. However, when the first on-treatment scan showed an increase in the size of the lung cancer it became obvious that this case was far from typical. Moderated by Dr. D. Ross Camidge, who provided a remote second opinion on the case, the patient, Mr. Bill Brand, and his primary oncologist, Dr. Ron Natale, discuss the twists and turns in the diagnosis and provide crucial insights on the nuances of understanding molecular testing, the best way to use and not abuse remote second opinions, and how you can and should rapidly adapt a plan that isn’t working. Mr. Brand, who had to join one molecularly specific patient support group, leave and then join another different one, also provides advice for patients regarding self-advocacy and handling direct communication with physicians.

Disclaimer